Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1/2 6Phase 3 5Phase 1 2

Status

Completed 19Recruiting 5Terminated 3Active not recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1

Conditions

Rectal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 87Cyclophosphamide 75Nivolumab 55Specimen Handling 49fludarabine 48Magnetic Resonance Spectroscopy 44Carboplatin 42Biopsy 39Radiotherapy 32fludarabine phosphate 29Gemcitabine 28venetoclax 27Paclitaxel 27atezolizumab 26Ipilimumab 26Cisplatin 23Radiation 22Dexamethasone 22Radiosurgery 21durvalumab 20Rituximab 20Lenalidomide 19Temozolomide 17Bevacizumab 17Pemetrexed 16130-nm albumin-bound paclitaxel 16palbociclib 15Decitabine 15Cytarabine 15ibrutinib 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Active not recruiting × trifluridine tipiracil drug combination × Clear all
NCT04104139 2026-04-15

TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer

OHSU Knight Cancer Institute

Phase 1 Active not recruiting
19 enrolled
Gastrointestinal

Rectal Neoplasms

NCT05029882 2025-10-29

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab

AbbVie

Phase 1 Active not recruiting
520 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡